AR128023A1 - Ligandos de anhidrasa carbónica ix - Google Patents

Ligandos de anhidrasa carbónica ix

Info

Publication number
AR128023A1
AR128023A1 ARP220103498A ARP220103498A AR128023A1 AR 128023 A1 AR128023 A1 AR 128023A1 AR P220103498 A ARP220103498 A AR P220103498A AR P220103498 A ARP220103498 A AR P220103498A AR 128023 A1 AR128023 A1 AR 128023A1
Authority
AR
Argentina
Prior art keywords
amino acid
group
residue
xaa1
xaa2
Prior art date
Application number
ARP220103498A
Other languages
English (en)
Spanish (es)
Inventor
Frank Osterkamp
Aileen Hhne
Matthias Paschke
Dirk Zboralski
Eberhard Schneider
Christian Haase
Jan Ungewi
Anne Bredenbeck
Christiane Smerling
Ulrich Reineke
Ina Wilkening
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of AR128023A1 publication Critical patent/AR128023A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP220103498A 2021-12-17 2022-12-19 Ligandos de anhidrasa carbónica ix AR128023A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP2021086592 2021-12-17
EP2022054857 2022-02-25
EP2022057170 2022-03-18
EP2022057840 2022-03-24
EP2022067424 2022-06-24
EP2022079606 2022-10-24
EP2022081674 2022-11-11

Publications (1)

Publication Number Publication Date
AR128023A1 true AR128023A1 (es) 2024-03-20

Family

ID=84981172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103498A AR128023A1 (es) 2021-12-17 2022-12-19 Ligandos de anhidrasa carbónica ix

Country Status (13)

Country Link
US (1) US20250339569A1 (https=)
EP (1) EP4448544A2 (https=)
JP (1) JP2025503451A (https=)
KR (1) KR20240133798A (https=)
AR (1) AR128023A1 (https=)
AU (1) AU2022410422B2 (https=)
CA (1) CA3242384A1 (https=)
CL (1) CL2024001830A1 (https=)
IL (1) IL313536A (https=)
MA (1) MA66591A1 (https=)
MX (1) MX2024007454A (https=)
TW (1) TW202340226A (https=)
WO (1) WO2023111350A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243979A1 (en) * 2022-02-11 2025-04-30 C-Biomex Co., Ltd. Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses
AR133015A1 (es) * 2023-06-20 2025-08-20 Debiopharm Int Sa Compuesto radiomarcado para su uso en un método de tratamiento de enfermedades con anhidrasa carbónica ix positiva
WO2025023747A1 (ko) * 2023-07-25 2025-01-30 (주)씨바이오멕스 탄산탈수소효소 ⅸ를 표적으로 하는 펩타이드 구조체 및 이들의 용도
CN120943901A (zh) * 2025-05-29 2025-11-14 北京肿瘤医院(北京大学肿瘤医院) 经修饰的caix靶向环肽、核素标记物及其在肿瘤诊疗方面的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
WO2012016713A1 (en) 2010-08-05 2012-02-09 Ruprecht-Karls-Universität Heidelberg Tumour targeting with polypeptides
WO2013172954A1 (en) * 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
TW201919682A (zh) * 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Nrf2路徑的新穎化合物
WO2019096867A1 (en) 2017-11-14 2019-05-23 Debiopharm Research & Manufacturing S.A. Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b
WO2020084305A1 (en) * 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900525D0 (en) * 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
JP7801207B2 (ja) * 2019-07-08 2026-01-16 3ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
TWI765195B (zh) 2019-11-22 2022-05-21 行政院原子能委員會核能研究所 雙靶向碳酸酐酶第九型複合物及其造影劑

Also Published As

Publication number Publication date
WO2023111350A2 (en) 2023-06-22
MX2024007454A (es) 2024-09-02
WO2023111350A3 (en) 2023-07-27
KR20240133798A (ko) 2024-09-04
AU2022410422B2 (en) 2026-01-08
US20250339569A1 (en) 2025-11-06
EP4448544A2 (en) 2024-10-23
MA66591A1 (fr) 2025-05-30
CA3242384A1 (en) 2023-06-22
IL313536A (en) 2024-08-01
TW202340226A (zh) 2023-10-16
JP2025503451A (ja) 2025-02-04
AU2022410422A1 (en) 2024-07-04
CL2024001830A1 (es) 2024-12-06

Similar Documents

Publication Publication Date Title
AR128023A1 (es) Ligandos de anhidrasa carbónica ix
Shimomura et al. Calcium binding, quantum yield, and emitting molecule in aequorin bioluminescence
Albada et al. Highly active antibacterial ferrocenoylated or ruthenocenoylated Arg-Trp peptides can be discovered by an L-to-D substitution scan
Thomas et al. Gold compounds for catalysis and metal-mediated transformations in biological systems
JP2021506910A (ja) EphA2に特異的な二環ペプチドリガンド
CN116888138A (zh) 放射性药物缀合组合物及其用途
US9410958B2 (en) Alkyne-activated fluorogenic azide compounds and methods of use thereof
AU2017320913A1 (en) Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
JP2022514255A (ja) Psmaに特異的な二環式ペプチドリガンド
ATE540054T1 (de) Antimikrobielle theta defensine und verfahren zu deren verwendung
JP2020510683A (ja) 新規抗菌製剤
JP2025503451A5 (https=)
JP5190594B2 (ja) アゾペプチド複合体
CN107129519B (zh) 基于金属铱配合物的多肽荧光环化方法及环化多肽
ES2649898T3 (es) Catalizadores de alta eficiencia, preparación y uso de los mismos
Katsuma et al. Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity
Tran et al. Two-step activation prodrugs: Transplatin mediated binding of chemotherapeutic agents to vitamin B 12
Sato et al. Novel des-fatty acyl-polymyxin B derivatives with Pseudomonas aeruginosa-specific antimicrobial activity
Clausell et al. Synthesis and membrane action of polymyxin B analogues
Abd Elhameed et al. Modulation of the catalytic activity of a metallonuclease by tagging with oligohistidine
Hayashi et al. Chemical synthesis of dual labeled proteins via differently protected alkynes enables intramolecular FRET analysis
Agrawal et al. Calixarenes and their biomimetic applications
Thombare et al. Advancing Nitrile‐Aminothiol Strategy for Dual and Sequential Bioconjugation
Tsao et al. Lung calcium-dependent phospholipid-binding proteins: structure and function
ES2556135T3 (es) Derivados de caprazeno-1'''-amida